Background Several randomized control trials (RCTs) have showed that adding either
abiraterone acetate (AA) or docetaxel (D) to androgen-deprivation therapy (ADT) improves …

BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, received FDA
approval in 2011 for metastatic castration-resistant prostate cancer (mCRPC) patients who …

Objectives To assess the cost-effectiveness of systemic treatments for metastatic castration-
sensitive prostate cancer from the US healthcare sector perspective with a lifetime horizon …

Purpose Prostate cancer is the second leading cause of cancer death in men in the US.
Since 2015, landmark studies have demonstrated improved survival outcomes with the use …

Abiraterone acetate is an oral medication that has recently been granted approval for the
treatment of metastatic castration resistant prostate cancer (mCRPC) prior and/or after …

Purpose New therapies with diverse mechanisms of action are available for metastatic
castration-resistant prostate cancer (mCRPC). This study aims to evaluate the effectiveness …

Background Abiraterone acetate plus prednisone with androgen deprivation therapy is a
standard treatment option for patients with high-risk metastatic castration-sensitive prostate …

Background Abiraterone acetate (AA) increases overall survival (OS) in patients with
metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel …

Background: A major, yet precisely studied, shift has occurred in the treatment of advanced
hormone-sensitive prostate cancer (HSPC) by the addition of docetaxel to androgen …

Background Docetaxel is an established first-line therapy to treat metastatic castration-
resistant prostate cancer (mCRPC). Recently, abiraterone and cabazitaxel were approved …